See more : W.T.B. Financial Corporation (WTBFA) Income Statement Analysis – Financial Results
Complete financial analysis of MediWound Ltd. (MDWD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MediWound Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vornado Realty Trust (VNO) Income Statement Analysis – Financial Results
- 1399 Internet Technology Application Group Inc. (YSGG) Income Statement Analysis – Financial Results
- Silver Wolf Exploration Ltd. (SWLFF) Income Statement Analysis – Financial Results
- Tower Resources Ltd. (TWR.V) Income Statement Analysis – Financial Results
- Anhui Sunhere Pharmaceutical Excipients Co.,Ltd. (300452.SZ) Income Statement Analysis – Financial Results
MediWound Ltd. (MDWD)
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.69M | 26.50M | 23.76M | 21.76M | 31.79M | 3.40M | 2.50M | 1.56M | 601.00K | 259.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.11M | 13.33M | 14.99M | 14.22M | 11.85M | 2.09M | 1.58M | 2.16M | 2.52M | 2.79M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.58M | 13.17M | 8.77M | 7.55M | 19.94M | 1.31M | 918.00K | -600.00K | -1.92M | -2.53M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 19.15% | 49.69% | 36.91% | 34.67% | 62.73% | 38.61% | 36.78% | -38.51% | -319.13% | -975.29% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.47M | 10.18M | 10.26M | 7.70M | 4.97M | 4.07M | 5.46M | 7.07M | 6.02M | 5.35M | 3.64M | 1.56M | 3.02M |
| General & Administrative | 8.57M | 8.33M | 6.11M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 4.72M | 1.63M | 1.14M | 1.24M |
| Selling & Marketing | 2.80M | 2.04M | 3.39M | 3.23M | 4.06M | 4.19M | 5.36M | 8.40M | 9.28M | 8.83M | 2.26M | 0.00 | 0.00 |
| SG&A | 11.38M | 10.37M | 9.74M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 13.55M | 3.89M | 1.14M | 1.24M |
| Other Expenses | 24.00K | 958.00K | -710.00K | -144.00K | 1.17M | -751.00K | 56.00K | 66.00K | 59.00K | 49.00K | 57.00K | 33.00K | 24.00K |
| Operating Expenses | 18.87M | 21.51M | 19.99M | 16.39M | 15.45M | 5.27M | 14.61M | 19.56M | 19.31M | 18.90M | 7.58M | 2.73M | 4.29M |
| Cost & Expenses | 33.98M | 34.84M | 34.98M | 30.60M | 27.30M | 7.36M | 16.18M | 21.71M | 21.83M | 21.69M | 7.58M | 2.73M | 4.29M |
| Interest Income | 2.34M | 270.00K | 11.00K | 297.00K | 434.00K | 412.00K | 0.00 | 1.27M | 288.00K | 4.67M | 1.00K | 6.00K | 32.00K |
| Interest Expense | 427.00K | 8.92M | 903.00K | 832.00K | 925.00K | 892.00K | 478.00K | 847.00K | 444.00K | 2.11M | 2.44M | 673.00K | 591.00K |
| Depreciation & Amortization | 1.30M | 1.27M | 1.24M | 1.09M | 1.15M | 577.00K | 567.00K | 589.00K | 503.00K | 492.00K | 336.00K | 267.00K | 196.00K |
| EBITDA | -4.89M | -18.09M | -11.22M | -7.75M | 3.42M | -5.09M | -13.12M | -18.30M | -20.72M | -18.33M | -6.50M | 12.25M | -4.10M |
| EBITDA Ratio | -26.19% | -35.22% | -42.01% | -35.61% | 17.75% | -99.47% | -525.64% | -1,255.84% | -3,448.25% | -6,281.85% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.29M | -8.35M | -11.22M | -8.84M | 4.49M | -3.96M | -13.69M | -20.16M | -21.23M | -21.43M | -7.58M | -2.73M | -4.29M |
| Operating Income Ratio | -81.83% | -31.50% | -47.22% | -40.62% | 14.13% | -116.44% | -548.36% | -1,293.65% | -3,531.95% | -8,272.97% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.76M | -11.18M | -2.30M | -436.00K | -2.43M | -1.71M | -846.00K | 1.27M | -444.00K | 2.55M | -920.00K | 14.72M | -532.00K |
| Income Before Tax | -6.53M | -19.52M | -13.52M | -9.28M | 2.07M | -5.67M | -14.53M | -18.89M | -21.67M | -18.88M | -8.50M | 11.99M | -4.82M |
| Income Before Tax Ratio | -34.95% | -73.68% | -56.91% | -42.62% | 6.50% | -166.57% | -582.25% | -1,212.13% | -3,605.82% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 185.00K | 78.00K | 27.00K | 325.00K | -1.65M | -9.69M | 8.46M | -1.27M | 861.00K | -2.55M | 7.77M | -13.67M | 1.88M |
| Net Income | -6.72M | -19.60M | -13.55M | -9.60M | 3.72M | -1.06M | -22.15M | -18.89M | -22.09M | -18.88M | -15.35M | 10.94M | -6.17M |
| Net Income Ratio | -35.94% | -73.97% | -57.03% | -44.12% | 11.70% | -31.08% | -887.38% | -1,212.13% | -3,675.21% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| EPS Diluted | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| Weighted Avg Shares Out | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
| Weighted Avg Shares Out (Dil) | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and...
MediWound to Report Third Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
The label expansion will solidify NexoBrid's position in the EU as a safe and effective non-surgical treatment for burn patients of all ages The label expansion will solidify NexoBrid's position in the EU as a safe and effective non-surgical treatment...
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
NexoBrid complements PMI's portfolio, allowing it to provide a comprehensive solution for burn patients NexoBrid complements PMI's portfolio, allowing it to provide a comprehensive solution for burn patients
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
MediWound to join forces with 3M Health Care, world's largest wound care company in pivotal study for patients with venous leg ulcers MediWound to join forces with 3M Health Care, world's largest wound care company in pivotal study for patients...
MediWound Deploys NexoBrid® for Emergency Supply
YAVNE, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, addresses emergency demand for NexoBrid to treat the mass of burn casualties, inflicted by the war...
MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?
MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution R&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Full commercial launch of NexoBrid marks important first step to becoming...
Source: https://incomestatements.info
Category: Stock Reports